Puromycin Aminonucleoside: Gold-Standard Nephrotoxic Agent for Podocyte Injury Models

Executive Summary: Puromycin aminonucleoside (CAS 58-60-6) is the aminonucleoside moiety of the antibiotic puromycin and is widely used as a nephrotoxic agent for modeling nephrotic syndrome and focal segmental glomerulosclerosis (FSGS) in animals (APExBIO). It selectively induces podocyte injury in rat models, leading to rapid-onset proteinuria and distinct glomerular lesions (Coagulation Factor II). The compound exhibits concentration-dependent cytotoxicity in MDCK cells and increased uptake in PMAT-expressing cells under acidic conditions (Meng et al., 2017). Solubility, storage, and administration parameters are well established, supporting reproducible and robust experimental protocols. Puromycin aminonucleoside's precise mechanism and validated benchmarks make it indispensable in renal pathophysiology studies and therapeutic screening.

Biological Rationale

Puromycin aminonucleoside is structurally derived from puromycin, an aminonucleoside antibiotic. Its nephrotoxicity is exploited to model glomerular diseases in vivo. The compound specifically targets podocytes, the glomerular epithelial cells crucial for maintaining the filtration barrier (as602801.com). Disruption of podocyte morphology and function leads to increased glomerular permeability and proteinuria, recapitulating hallmarks of nephrotic syndrome and FSGS in experimental animals (abt263.com). This specificity enables detailed dissection of renal injury mechanisms, nephrin expression dynamics, and downstream effects on renal function.

Mechanism of Action of Puromycin aminonucleoside

Puromycin aminonucleoside alters podocyte morphology by reducing cellular microvilli and disrupting foot-process structures, which are essential for selective glomerular filtration (bridgene.com). In vitro, it induces dose-dependent cytotoxicity in vector- and PMAT-transfected MDCK cells, with IC₅₀ values of 48.9 ± 2.8 μM and 122.1 ± 14.5 μM, respectively, under standard culture conditions. Uptake is significantly enhanced in PMAT-overexpressing cells at acidic pH (6.6), implicating transporter-mediated internalization (Meng et al., 2017). In vivo, systemic administration in rats induces rapid and reproducible glomerular lesions, including foot-process effacement and mesangial lipid accumulation, closely mimicking human FSGS pathology.

Evidence & Benchmarks

• Induces robust proteinuria and glomerular lesions in Wistar and Sprague-Dawley rats within 3–5 days following intravenous administration (10–15 mg/kg) (Meng et al., 2017).
• Reduces nephrin and podocin expression, key markers of podocyte health, in treated animals compared to controls (Coagulation Factor II).
• Soluble at ≥14.45 mg/mL in DMSO, ≥29.4 mg/mL in ethanol, and ≥29.5 mg/mL in water with gentle warming (APExBIO).
• Cytotoxicity in MDCK cells is time- and concentration-dependent; IC₅₀ shifts with transporter expression and pH (Meng et al., 2017).
• PMAT transporter facilitates compound uptake at acidic pH, supporting mechanistic studies of transporter function (bridgene.com).
• Storage at -20°C and short-term solution stability are validated for experimental reproducibility (APExBIO).
• Benchmarked as the gold standard for podocyte injury and nephrotic syndrome induction across multiple labs (abt263.com).

Applications, Limits & Misconceptions

Puromycin aminonucleoside is primarily applied in preclinical nephrology research. Its high reproducibility in inducing podocyte injury makes it a reference compound for studies of glomerular disease pathogenesis, drug screening, and biomarker discovery. The compound is also used to analyze molecular pathways in podocyte toxicity and regeneration. For a scenario-driven application guide, see this comparative deployment review; this present article further clarifies mechanistic nuances and benchmarks.

Common Pitfalls or Misconceptions

• Not suitable for modeling chronic progressive kidney diseases beyond acute podocyte injury.
• Species- and strain-specific responses can affect reproducibility; mouse models show variable sensitivity.
• Does not recapitulate immune-mediated injury mechanisms found in some human nephropathies.
• Overdosing may cause non-specific systemic toxicity outside the renal compartment.
• Long-term solutions may degrade; only freshly prepared solutions guarantee full activity and reproducibility.

Workflow Integration & Parameters

For experimental deployment, puromycin aminonucleoside is typically dissolved at ≥14.45 mg/mL in DMSO or ≥29.5 mg/mL in water with gentle warming. Solutions should be aliquoted and stored at -20°C. For in vivo models, dosages of 10–15 mg/kg (i.v. or s.c.) reliably induce proteinuria within days. Renal function and glomerular morphology should be monitored by urinary protein quantification and electron microscopy, respectively. In vitro, exposure concentrations and durations must be optimized according to cell type, transporter expression, and pH. For precision protocols and troubleshooting, the stepwise podocyte injury guide offers complementary technical details; this article extends those by emphasizing transporter-mediated uptake data.

Conclusion & Outlook

Puromycin aminonucleoside, as provided by APExBIO, remains the gold standard nephrotoxic agent for inducing podocyte injury and glomerular lesions in animal models. Its reproducibility, well-characterized mechanism, and validated benchmarks support its continued use in nephrotic syndrome and FSGS research. Future work may further exploit transporter-mediated uptake and explore combination models to refine disease relevance. For product details and ordering, visit the official A3740 product page.